SOLB:EURONEXT BRUSSELSSolvay SA Analysis
Data as of 2026-05-25 - not real-time
€26.20
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Solvay trades around €26, just above its DCF‑derived fair value, indicating limited upside. The stock offers a high single‑digit dividend yield, backed by a very low payout ratio, suggesting sustainability. Technicals show a bearish MACD histogram and decreasing volume, pointing to short‑term pressure. RSI sits near the mid‑range, and the price is comfortably above the identified support but still below the near‑term resistance. Beta is exceptionally low, implying minimal market‑wide price swings, yet 30‑day volatility exceeds 30%, reflecting internal price swings. Recent shareholder meeting minutes reveal strong backing for management’s strategy, adding governance confidence.
Fundamentals reveal flat to negative revenue growth and modest margins, limiting organic growth prospects. The balance sheet carries a high debt‑to‑equity ratio, but ample cash and positive free cash flow cushion liquidity. The valuation metrics place the stock in the “value” camp, with a forward P/E around 10 and a price‑to‑book above 2.5. Given the combination of a generous dividend, defensive beta, and modest valuation headroom, the stock is best viewed as a dividend‑focused value play. Investors should be cautious of the bearish short‑term technical signals and the sector’s sensitivity to commodity cycles. Overall, the recommendation leans toward holding with a view to accumulate on dips while monitoring cash flow and debt trends.
Fundamentals reveal flat to negative revenue growth and modest margins, limiting organic growth prospects. The balance sheet carries a high debt‑to‑equity ratio, but ample cash and positive free cash flow cushion liquidity. The valuation metrics place the stock in the “value” camp, with a forward P/E around 10 and a price‑to‑book above 2.5. Given the combination of a generous dividend, defensive beta, and modest valuation headroom, the stock is best viewed as a dividend‑focused value play. Investors should be cautious of the bearish short‑term technical signals and the sector’s sensitivity to commodity cycles. Overall, the recommendation leans toward holding with a view to accumulate on dips while monitoring cash flow and debt trends.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD histogram
- Decreasing trading volume
- Price near mid‑range resistance
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- High single‑digit dividend yield with low payout ratio
- DCF fair value close to market price suggesting limited downside
- Strong shareholder support for strategic direction
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustainable dividend backed by solid free cash flow
- Defensive beta and low market‑wide volatility
- Strategic exposure to battery and specialty chemicals markets
Key Metrics & Analysis
Financial Health
Revenue Growth-8.10%
Profit Margin-0.54%
P/E Ratio9.9
ROE-1.46%
ROA4.05%
Debt/Equity185.94
P/B Ratio2.7
Op. Cash Flow€660.0M
Free Cash Flow€340.5M
Technical Analysis
TrendNeutral
RSI45.6
Support€24.56
Resistance€29.16
MA 20€26.83
MA 50€26.78
MA 200€27.06
MACDBearish
VolumeDecreasing
Fear & Greed Index91.75
Valuation
Fair Value€26.19
Target Price€24.94
Upside/Downside-4.79%
GradeOvervalued
TypeValue
Dividend Yield9.35%
Risk Assessment
Beta0.08
Volatility31.72%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.